You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Patients

How do you know which treatment is right for a patient? It can be a tricky question to answer. Below are some patient profiles to help you identify patients that may benefit from GSK’s COPD treatments.

Discover Anoro Ellipta

Meet Hannah

Age:

56 years

Presentation:

Recently diagnosed with COPD, struggles with breathlessness despite daily SABA use.

Discover Trelegy Ellipta

Could Anoro Ellipta (umeclidinium/vilanterol) help?

Prescribing information

Indication

Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 4

Discover Trelegy Ellipta

Meet Sylvia

Presentation:

She is on treatment with an ICS/LABA, symptomatic and at risk of an exacerbation:

  • Has worsening of symptoms, or
  • Has experienced an exacerbation treated with antibiotics or oral corticosteroids, in the past 12 months.
Discover Trelegy Ellipta

Could Trelegy Ellipta
(fluticasone furoate / umeclidinium / vilanterol) help?

Prescribing information

Indication

Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA. 3

Studies

The safety and efficacy profile of our COPD treatments have been studied in clinical trials. Do you want to learn more? You can explore the studies here:

Anoro vs. tiotropium 1

Interested in whether dual bronchodilator Anoro Ellipta (UMEC/VI) could improve outcomes for your patients with COPD compared to using tiotropium alone? If so, this pooled post hoc analysis is for you.

Show me the data

The IMPACT Trial 2

This landmark trial compared the once-daily triple therapy Trelegy Ellipta (FF/UMEC/VI) with once-daily dual therapies (an ICS/LABA and a LAMA/LABA). 2 Find out how Trelegy Ellipta can help patients with COPD.

Find out about IMPACT

Your resources

Benefit from expert opinion and free downloadable resources, including training devices and COPD Assessment Test (CAT) pads.

Watch the experts

You’ll hear how medical experts tackle some of the key issues in COPD management and what this could mean for your patients.

View expert videos

Order the CAT pad

Assess the impact COPD is having on your patients’ lives by using the COPD Assessment Test (CAT).

Order now

Free resources

Need an Ellipta training inhaler? Or simply looking for some patient resources on COPD? Then this is the place for you.

View all Resources

Abbreviations

CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic receptor antagonist

References:

  1. Maleki-Yazdi M, et al. Adv Ther. 2016; 33:2188-2199.
  2. Lipson DA, et al. N Engl J Med. 2018; 378:1671-1680.
  3. Trelegy Ellipta SmPC.
  4. Anoro Ellipta SmPC.

Trademarks are the property of their respective owners. Anoro Ellipta and Trelegy Ellipta were developed in collaboration with INNOVIVA

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.